By: Taylor Cruz, MPH, RD, LDN, CDCES
Over the past few years, medications like Ozempic, Wegovy, and Mounjaro have become a major part of conversations about health, food, and body size. What began as medications developed for specific medical purposes has evolved into a much broader cultural conversation about weight loss, appetite suppression, and the pursuit of smaller bodies.
For some people, GLP-1 medications offer meaningful medical benefits and are an important part of managing chronic health conditions. For others, the growing popularity of these medications has brought renewed pressure to lose weight, eat less, or view a smaller body as the ultimate marker of health and success.
These conversations can be particularly complicated for people with current or past eating disorders, those working toward recovery, or anyone who has struggled with their relationship with food and body image.
At Lutz, Alexander & Associates Nutrition Therapy, we believe it’s important to separate the medical use of GLP-1 medications from the diet culture messaging that often surrounds them. We acknowledge the potential benefits of these medications while also recognizing that appetite suppression, weight loss, and changes in eating patterns deserve thoughtful consideration, especially in the context of eating disorder recovery.
Let’s take a closer look at the relationship between GLP-1s (such as Ozempic), eating disorders, and this new iteration of diet culture.
Ozempic, GLP-1s, and the Resurgence of Diet Culture
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, are a class of medications that affect blood sugar regulation, digestion, appetite, and feelings of fullness. They were initially developed to help manage Type 2 diabetes, and certain medications in this class are also FDA-approved for “chronic weight management” and other medical indications.
You may recognize some of the more commonly discussed medications:
- Ozempic (semaglutide): FDA-approved for specific uses related to Type 2 diabetes, including blood sugar management and reducing certain cardiovascular and kidney-related risks.
- Wegovy (semaglutide): FDA-approved for “chronic weight management” in adults and adolescents aged 12 and older, as well as for metabolic-associated liver disease (MAFLD/MASH), and for reducing the risk of adverse cardiovascular events in adults. Wegovy and Ozempic are the same medication marketed under 2 different names. Although both medications have the same initial doses, Wegovy has higher maximum maintenance doses than Ozempic.
- Mounjaro (tirzepatide): FDA-approved to improve blood glucose management in adults and children ages 10 and older with Type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with Type 2 diabetes who are at high risk.
- Zepbound (tirzepatide): FDA-approved for chronic weight management in adults with “obesity” or “overweight” with at least one weight-related medical condition, and for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Important distinction: Mounjaro and Zepbound contain the same active medication (tirzepatide) and have the same available dose strengths (2.5–15 mg once weekly), but have different FDA-approved indications. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both GIP and GLP-1 receptors, whereas semaglutide (Ozempic/Wegovy) activates only GLP-1 receptors.
Although these medications have legitimate medical uses, their growing visibility in celebrity conversations, social media, and popular culture has shifted much of the public discussion toward weight loss. In our practice, we work with many clients who take GLP-1 medications, and we’ve seen a wide range of experiences. For some, these medications have been quite helpful; for others, they’ve been harmful; and for many, navigating treatment has meant weighing both the benefits and the drawbacks. The reality is that these medications are complex, and the conversations surrounding them deserve nuance, rather than a one-size-fits-all perspective.
GLP-1 medications are frequently discussed as tools for achieving a smaller body, controlling appetite, or making it easier to eat less. Social media conversations may celebrate reduced hunger, smaller portions, or changes in clothing size as evidence of success.
This messaging can reinforce familiar diet culture beliefs, including:
- Smaller bodies are inherently healthier or more desirable.
- Eating less is always a positive accomplishment.
- Hunger is something to suppress or overcome.
- Weight loss is a measure of personal discipline or success.
- People should pursue weight loss even when it isn’t aligned with their individual medical needs or well-being.
These messages aren’t new. Diet culture has long encouraged people to prioritize thinness, ignore hunger, and view food as something that needs to be controlled. GLP-1 medications have simply introduced a new way for these familiar messages to show up.
The distinction matters. Making an informed medical decision with a healthcare provider is not the same as feeling pressured to change your body because of cultural expectations.
People deserve access to appropriate medical care without being made to feel that their bodies need to change to be worthy of health, respect, or acceptance.
Understanding the Connection Between GLP-1s and Eating Disorders
The relationship between Ozempic, other GLP-1 medications, and eating disorders is complex. These medications can affect appetite, hunger, fullness, digestion, and eating patterns. While these effects could be challenging for anyone to navigate, they are particularly complicated for people with current or past eating disorders.
For someone with a history of restrictive eating, for example, experiencing less hunger or having difficulty eating consistently may bring up familiar thoughts and behaviors. If eating less has historically felt like an accomplishment or a source of control, medication-related changes in appetite may reinforce those patterns.
People with a history of binge eating may also have complicated experiences. Changes in appetite, preoccupation with food, or experiencing eating differently can bring up unexpected emotions or concerns. While GLP-1 medications are being studied for their potential role in treating binge eating, the research is still developing. GLP-1 medications are not an established treatment for any eating disorder.
Some potential concerns to consider include:
- Reduced hunger cues: When a medication changes appetite, recognizing and responding to the body’s need for nourishment may become more challenging. This can be particularly complicated for people who are rebuilding trust in their hunger and fullness cues.
- Difficulty maintaining consistent nourishment: Reduced appetite, nausea, or other gastrointestinal side effects may make it harder to eat regularly and meet nutritional needs.
- Reinforcement of restrictive thoughts: If someone has a history of restrictive eating, experiencing less hunger or eating smaller amounts may reinforce existing eating disorder thoughts or behaviors.
- Increased food and body preoccupation: Changes in appetite or body size may lead to increased attention to food intake, weight, or perceived success and failure.
It’s important to emphasize that not everyone who takes Ozempic or another GLP-1 medication will develop disordered eating. Medication effects and individual experiences vary, and taking a GLP-1 medication does not automatically mean someone has an eating disorder.
It’s also important to recognize that eating disorders occur across body sizes. A person’s appearance or body size cannot determine whether they are struggling with an eating disorder or whether they need additional support.
In my experience, individuals in larger bodies are often offered GLP-1 medications by their providers without any assessment of their relationship with food or history of disordered eating. This is certainly an area where improvement is needed. Emerging clinical recommendations highlight the importance of screening for current and past eating disorders before starting GLP-1 medications and monitoring for changes in eating disorder symptoms during treatment. A 2026 international consensus study also emphasizes that active restrictive eating disorders warrant particular clinical attention when considering these medications (Keshen et al., 2026).
The goal isn’t to assume that GLP-1 medications are inherently harmful. It’s to recognize that people with eating disorder histories deserve thoughtful, individualized care that considers both their medical needs and their relationship with food.
Supporting Your Relationship With Food While Navigating GLP-1s
Whether you’re currently taking a GLP-1 medication, considering one, or simply feeling overwhelmed by the surrounding cultural conversation, there are ways to protect your relationship with food and support your recovery.
Here are six considerations:
- Separate medical decisions from diet culture pressure.
Take time to consider why you are interested in a medication and what you hope it will address. Are you discussing a specific medical concern with your healthcare provider, or are you feeling pressure to change your body because of messages from friends, family, social media, or society?
There is a difference between making an informed medical decision and feeling that you need to pursue weight loss to be accepted or valued.
- Stay connected to consistent nourishment.
Your body still needs adequate and consistent nourishment, even when medication affects your hunger or appetite. Changes in hunger cues don’t mean your nutritional needs disappear.
If you’re having difficulty eating regularly or meeting your nutritional needs, an eating disorder-informed registered dietitian can help you explore supportive strategies that account for your individual circumstances.
- Pay attention to changes in your relationship with food.
Notice whether you’re experiencing increased food anxiety, rigid food rules, guilt around eating, or a growing preoccupation with body changes.
These experiences don’t automatically mean you’re relapsing, but they may be signs that additional support would be helpful. You don’t have to wait until things feel overwhelming to reach out.
- Avoid comparing your experience with others.
People have different medical histories, nutritional needs, treatment goals, and experiences with medication. Someone else’s appetite, response to medication, or body changes don’t determine what is appropriate for you.
Social media often presents simplified versions of complicated medical experiences. You are not seeing the full picture of someone else’s health or treatment.
- Maintain your eating disorder recovery support.
If you’re in recovery, staying connected with your treatment team can be particularly important when navigating GLP-1 conversations or medication-related changes.
A registered dietitian and therapist who understand eating disorders can help you work through food anxiety, changes in appetite, and body image concerns while coordinating with your prescribing clinician.
- Make room for body image challenges.
It’s okay if the growing cultural focus on weight loss feels difficult. You can acknowledge those feelings without acting on every thought or comparison that comes up.
Consider setting boundaries around conversations or social media content that leave you feeling anxious about food or your body. Give yourself permission to step away from discussions that don’t support your recovery.
You don’t have to agree with every cultural message about weight and health. You can make space for your own values and recovery goals, even when they look different from what is being celebrated around you.
A Weight-Inclusive Approach to GLP-1s and Eating Disorder Recovery
At Lutz, Alexander & Associates Nutrition Therapy, we believe people deserve compassionate, individualized nutrition care regardless of their body size, medication choices, or stage of recovery from an eating disorder.
A weight-inclusive approach doesn’t mean dismissing medical concerns or rejecting medication. It means recognizing that health is complex and that weight alone cannot tell us whether someone is healthy, adequately nourished, or experiencing a positive relationship with food.
When it comes to GLP-1 medications, this means acknowledging their legitimate medical uses while also considering how appetite changes, nutritional needs, food anxiety, and body image may intersect with eating disorder recovery.
An eating disorder-informed registered dietitian can help you navigate these experiences, develop supportive approaches to consistent nourishment, and work through changes in your relationship with food. They can also collaborate with your prescribing clinician and mental health provider to ensure your nutritional and recovery needs remain part of the conversation.
Our team at Lutz, Alexander & Associates Nutrition Therapy provides non-diet, weight-inclusive, trauma-informed, and recovery-focused nutrition therapy. We work with individuals navigating eating disorders, disordered eating, body image concerns, and a variety of medical conditions.
You don’t need to be actively struggling with an eating disorder to benefit from support. Whether you’re taking a GLP-1 medication, considering one, or finding that the surrounding conversations are bringing up difficult feelings about food and your body, you deserve a space where those experiences can be discussed without judgment.
Taking a GLP-1 medication doesn’t make you any less deserving of eating disorder recovery support. And choosing not to take one doesn’t mean you’re missing out on a necessary health intervention.
Your health is about more than your weight, and your recovery deserves to remain a priority.
If you’re looking for support navigating GLP-1 medications, your relationship with food, or eating disorder recovery, we’d love to help. Lutz, Alexander & Associates Nutrition Therapy offers individualized nutrition therapy and eating disorder support through our North Carolina and Oregon locations. Contact our team to learn more about working with one of our registered dietitians.
- Keshen et al. (2026). Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: A modified Delphi study. World Psychiatry, 25(3), 465–474.


